Products
Trosunilimab Biosimilar Monoclonal Antibody (Integrin α4β7) for Research
Cat No.: GMP-Bios-INN-1429
Anti-ITGA4B7 therapeutic antibody (Pre-made Trosunilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Trosunilimab (development code PR-1794842) is a humanized monoclonal antibody targeting integrin alpha-4 beta-7 (ITGA4/ITGB7). It is developed by AbbVie for Crohn's Disease, Ulcerative Colitis in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1429-1mg | 1mg | 3090 |
| GMP-Bios-INN-1429-10mg | 10mg | |
| GMP-Bios-INN-1429-100mg | 100mg | |
| GMP-Bios-INN-1429-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Trosunilimab biosimilar, Whole mAb, Anti-ITGA4B7 Antibody: Anti-Integrin Alpha 4/Integrin alpha-4/ITGA4/CD49d therapeutic antibody |
| INN Name | Trosunilimab |
| Target | ITGA4B7 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | na |
